Fibrosis Frontiers: From Basic Mechanisms to Precision Therapies

Jan 01–04, 2027 | Location to be Determined
Scientific Organizers: Rafael Kramann, Rebekka Schneider-Kramann, and Neil C. Henderson

  In Person
  On Demand
×

-

Jan 01–04, 2027 | Location to be Determined

Scientific Organizers: Rafael Kramann, Rebekka Schneider-Kramann, and Neil C. Henderson

Supported by the  Directors' Fund

***Meeting program subject to change.

Available Formats:   = In Person     = On Demand
Friday, January 1, 2027
Registration
4:00–8:00 PM
Welcome Mixer
6:00–8:00 PM
Saturday, January 2, 2027
Breakfast
7:00–8:00 AM
Welcome and Keynote Address
8:00–9:00 AM
Carine Boustany †, Boehringer Ingelheim
Drug Discovery in Fibrosis
Developing Novel Therapeutics in Fibrotic Disease
9:00–11:15 AM
Thomas A Wynn †, Pfizer
Anti-Inflammatory Therapeutics in Organ Fibrosis
Paul J. Yaworsky †, Mediar Therapeutics
Targeting EphrinB2 and WISP1 in Liver and Pulmonary Fibrosis
Catherine Hines †, GlaxoSmithKline
Biomarkers and Imaging as Readouts in Clinical Testing
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
Meet the Editors
11:15–12:15 PM
Poster Setup
12:15–1:00 PM
On Own for Lunch
12:15–5:00 PM
Poster Viewing
1:00–10:00 PM
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
From Identification of Novel Therapies to Early Clinical Testing in Fibrosis
5:00–7:00 PM
Lisa Lancaster †, Vanderbilt University Medical Center
Endpoints in Clinical Trials in Fibrosis
Rebekka Schneider †, Erasmus MC
From Single Cell Genomics to Novel Targets in Fibrotic Disease and Clinical Testing
Frank A. Anania †, US Food and Drug Administration
Regulatory Steps Towards Approval of Novel Antifibrotic Therapies
Short Talk(s) Chosen from Abstracts
Social Hour with Dinner
7:00–8:00 PM
Posters
7:30–10:00 PM
Sunday, January 3, 2027
Breakfast
7:00–8:00 AM
Mapping Fibrotic Disease using Single Cell and Spatial Genomics
8:00–11:00 AM
Rafael Kramann, RWTH Aachen University
Mapping Kidney and Cardiac Fibrosis to Identify Novel Therapeutic Targets
Neil C. Henderson, Institute of Regeneration and Repair, University of Edinburgh
Spatial Mapping of Human Liver Fibrosis
Bethan Psaila †, University of Oxford
Single Cell Mapping of Myelofibrosis
Benjamin D. Humphreys †, Washington University
Single Cell and Spatial Genomics to Map Kidney Fibrosis
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
Panel Discussion 1: How to Launch a Startup
11:00–12:00 PM
Poster Setup
12:00–1:00 PM
On Own for Lunch
12:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Career Roundtable
3:00–4:30 PM
Coffee Available
4:30–5:00 PM
Fibrosis in Cancer and Aging
5:00–7:00 PM
Natalie J. Torok †, Stanford University
The Role of Matrix in Liver Cancer Progression and Aging
Simon Mendez-Ferrer †, University of Cambridge
Mechanisms of Fibrosis Hematopoietic Malignancies
Melanie Koenigshoff †, University of Pittsburgh
Role of Senescence and Aging in Pulmonary Fibrosis
Short Talk(s) Chosen from Abstracts
Social Hour with Dinner
7:00–8:00 PM
Posters
7:30–10:00 PM
Monday, January 4, 2027
Breakfast
7:00–8:00 AM
Organ Specific and Conserved Mechanisms of Organ Fibrosis
8:00–11:00 AM
Jörg H.W. Distler †, University Hospital Düsseldorf
Mechanisms of Pulmonary and Skin Fibrosis
Vincent F Fiore †, Boehringer Ingelheim
Mechanisms of Fibrosis in IBD, Boehringer Ingelheim
Katalin Susztak †, University of Pennsylvania
Mechanisms of Kidney Fibrosis
Kory J. Lavine †, Washington University School of Medicine
Mechanisms of Cardiac Fibrosis
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
Panel Discussion 2: Why Are We not Seeing Progress / Therapeutic Success in Some Areas? What Are We Missing and How can We Address these Challenges/ Lessons from Clinical Trials?
11:00–12:00 PM
On Own for Lunch
12:00–5:00 PM
Symposia Spotlight 2: AI & Big Data in Drug Development
2:30–4:30 PM
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
Need for Multimodal Therapies, New Modalities and Lessons Learned from Clinical Trials
5:00–6:45 PM
Grant Budas †, Gilead
Multimodal Therapies for Fibrotic Disease
Shelia M. Violette †, Q32 Bio
Immunotherapies and New Modalities for Fibrotic Disease
Scott L Friedman †, Icahn School of Medicine at Mount Sinai
Lessons Learned from Clinical Trials and Regulatory Aspects in Fibrotic Disease
Short Talk(s) Chosen from Abstracts
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Social Hour with Dinner
7:00–8:00 PM
Entertainment
8:00–11:00 PM
Cash Bar
8:00–11:00 PM
Tuesday, January 5, 2027
Departure
12:00–11:59 PM

Subscribe for Updates